探索发现新型CDK12抑制剂的探索
Abhijit Debnath1, Rajesh Kumar Singh2, Rupa Mazumder1
1Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, India.
Journal of receptor and signal transduction research
|December 19, 2024
概括
研究人员确定了一种新型小分子,ZINC11784547,作为循环林依赖激酶12 (CDK12) 的强有力的抑制剂. 这种化合物通过有效抑制癌细胞生长和促进细胞死亡,对癌症治疗具有前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 循环林依赖激酶12 (CDK12) 在RNA处理,转录和细胞周期调节中起着至关重要的作用.
- CDK12被认为是各种癌症的致癌因子,包括乳腺癌,甲状腺癌,肝癌,前列腺癌和尤宁肉瘤,因此它是一个重要的生物标志物和治疗点.
- 寻求小分子抑制剂作为针对CDK12向癌症治疗的单克隆抗体的负担得起的替代品.
研究的目的:
- 通过高通量虚拟查来确定CDK12的有效和负担得起的小分子抑制剂.
- 评估潜在的候选药物,以评估它们的结合亲和力,药理动力学特性,毒性和对癌细胞的疗效.
主要方法:
- 使用RASPD协议对三个数据库进行虚拟选,以对抗CDK12.
- 进行了药物相似性,分子对接,ADME/毒性预测,共识分子对接和MD模拟.
- 进行了体外研究,包括MTT测定,以评估已识别的化合物的细胞毒性作用.
主要成果:
- 确定ZINC11784547作为一个有前途的CDK12抑制剂.
- ZINC11784547表现出强大的结合亲和力,有利的ADME特性,低毒性和显著的稳定性.
- 该化合物表现出显著的细胞毒性作用,表明它有可能诱导癌细胞死亡.
结论:
- ZINC11784547是一种强大的CDK12小分子抑制剂,具有有利的类似药物的特性,并在临床前评估中证明有效性.
- 这种化合物代表了开发新型CDK12向癌症治疗的有希望的候选者,提供了潜在的更容易获得的治疗选择.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Positive Regulator Molecules
5.3K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


